Publications by authors named "D Slamon"
Article Synopsis
- The NATALEE trial evaluated the effectiveness of ribociclib in combination with nonsteroidal aromatase inhibitors (NSAI) compared to NSAI alone over three years for treating HR+/HER2- early breast cancer patients.
- The study involved 5,101 patients who were randomized to receive either ribociclib plus NSAI or NSAI alone, with the primary focus on invasive disease-free survival (iDFS).
- Results showed that ribociclib plus NSAI significantly improved iDFS, with 90.7% of patients remaining disease-free compared to 87.6% for those on NSAI alone, while safety profiles remained consistent with no new safety concerns.
There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that evaluates cfDNA fragmentomes and protein biomarkers to detect ovarian cancer.
View Article and Find Full Text PDFArticle Synopsis
- A study analyzed paired baseline and end-of-treatment circulating tumor DNA (ctDNA) samples from the MONALEESA trials to identify genetic changes in patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy (ET) or a placebo.
- The analysis included 523 samples, revealing 21 genes with significant alterations at end-of-treatment, particularly highlighting increased mutations in RB1 and SPEN in the ribociclib group, while ESR1 mutations were noted in both treatment arms.
- The findings suggest acquired genetic alterations related to treatment response and resistance, providing insights for future research on resistance mechanisms and potential systemic therapies following CDK4/6 inhibitors.
Article Synopsis
- Intrinsic breast cancer molecular subtyping (IBCMS) is important for predicting outcomes and guiding treatment in breast cancer patients.
- This study evaluated various IBCMS methods and gene-expression platforms in two clinical trials (PALOMA-2 and PALLET) and found differing levels of agreement in molecular subtype assignments.
- The results emphasize the need for standardized approaches in IBCMS to avoid potential misguidance in treatment decisions.